Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate
Halima Moncrieffe, Mark F Bennett, Monica Tsoras, Lorie K Luyrink, Anne L Johnson, Huan Xu, Jason Dare, Mara L Becker, Sampath Prahalad, Margalit Rosenkranz, Kathleen M O'Neil, Peter A Nigrovic, Thomas A Griffin, Daniel J Lovell, Alexei A Grom, Mario Medvedovic, Susan D Thompson
Rheumatology | OXFORD UNIV PRESS | Published : 2017
Objective: The mechanisms that determine the efficacy or inefficacy of MTX in JIA are ill-defined. The objective of this study was to identify a gene expression transcriptional signature associated with poor response to MTX in patients with JIA. Methods: RNA sequencing was used to measure gene expression in peripheral blood mononuclear cells collected from 47 patients with JIA prior to MTX treatment and 14 age-matched controls. Differentially expressed baseline genes between responders and non-responders were evaluated. Biological differences between all JIA patients and controls were explored by constructing a signature of differentially expressed genes. Unsupervised clustering and pathway ..View full abstract
Awarded by National Institute of Arthritis and Musculoskeletal and Skin Diseases of National Institutes of Health
This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [Grant Award Numbers P01AR048929, P30AR47363, P30AR070549, and P30AR070253] and in part by the Cincinnati Children's Research Foundation and its Cincinnati Genomic Control Cohort, as well as Fundacion Bechara. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.